This article first appeared on GuruFocus .
ETFs bought $22.0 million of Merck ( MRK ) on Thursday, with 36 funds adding shares against 20 that sold. ETF activity has favored the stock for four straight sessions, including $19.1 million on Wednesday and $12.3 million on Monday. The run follows net selling of $25.3 million on Oct. 23. A further 147 ETFs held their positions unchanged.
See all ETF and guru trades in MRK on its MRK guru trades page .
Which ETFs bought MRK on Thursday?
The largest buyers by dollar value were XLV ($22.9 million), DIA ($2.2 million) and IWD ($1.4 million). In all, 36 ETFs added shares and 20 cut them.
| ETF |
Shares changed |
Value |
Weight in ETF |
|---|---|---|---|
| +156,768 |
$22.9M |
5.42% |
|
| +14,835 |
$2.2M |
1.66% |
|
| +9,295 |
$1.4M |
0.95% |
|
| +4,420 |
$0.6M |
1.18% |
|
| +3,430 |
$0.5M |
1.77% |
|
| +3,396 |
$0.5M |
0.52% |
|
| +2,676 |
$0.4M |
2.30% |
|
| +2,250 |
$0.3M |
0.54% |
The Health Care Select Sector SPDR ( XLV ) drove the move, adding 156,768 shares worth $22.9 million, lifting its stake 0.88% to 18,050,183 shares at a 5.42% weight. The SPDR Dow Jones Industrial Average ETF ( DIA ) added $2.2 million and the iShares Russell 1000 Value ETF ( IWD ) $1.4 million, while SPDR Portfolio S&P 500 Value ( SPYV ) added $0.6 million. Merck sits in the Healthcare sector, in the Drug Manufacturers - General industry, with a market cap of $368.9 billion.
Have ETFs been buying or selling MRK lately?
Over the last 5 reported days, ETFs were net buyers on 4 and net sellers on 1, so the recent trend is mostly buying.
| Date |
Net value |
Buying |
Selling |
|---|---|---|---|
| Oct. 29 |
$22.0M |
36 |
20 |
| Oct. 28 |
$19.1M |
33 |
11 |
| Oct. 27 |
$4.9M |
29 |
15 |
| Oct. 26 |
$12.3M |
23 |
17 |
| Oct. 23 |
-$25.3M |
25 |
15 |
What does MRK do?
Merck is a global health care company delivering innovative health solutions through prescription medicines, biologic therapies, vaccines, and animal health products, with total sales of $65.0 billion in 2025.
Merck reported trailing-12-month revenue of $67.19 billion, up 6.6% over one year, with a gross margin of 74.0% and a net margin of 3.6%. The stock trades at a P/E of 152.73, a P/B of 8.8 and a P/S of 5.51, against a market cap of $368.9 billion. Its GF Score is 81, and at a price of $149.52 it sits above the GF Value of $121.23. The dividend yield is 2.36%, and the shares have returned 44.98% year to date.
MRK at a glance
| Measure |
Value |
|---|---|
| Price |
$149.52 |
| Market cap |
$368.90B |
| Revenue (trailing 12 months) |
$67.19B |
| Revenue growth (1 year) |
+6.6% |
| Gross margin |
74.0% |
| Net margin |
3.6% |
| P/E |
152.73 |
| P/B |
8.80 |
| P/S |
5.51 |
| 81/100 |
|
| GF Value |
$121.23 |
| Dividend yield |
2.36% |
| Year-to-date return |
+44.98% |
For a closer look, open the MRK stock summary , its GF Value chart and insider buying and selling .
More on GuruFocus: ETF Trends | ETF Screener
What should investors watch next for MRK?
Watch whether Merck's four-day ETF buying streak holds, given the swing from $25.3 million in net selling on Oct. 23.
Based on ETF holdings changes reported for Oct. 29, 2026.
